Sweet’s Syndrome (SS) in the Course of Acute Myeloid Leukaemia (AML)
Author(s) -
Claudio Guarneri,
Uwe Wollina,
Torello Lotti,
Georgi Konstantinov Maximov,
Ilia Lozev,
Serena Gianfaldoni,
Ivan Pidakev,
Jacopo Lotti,
Georgi Tchernev
Publication year - 2018
Publication title -
open access macedonian journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.288
H-Index - 17
ISSN - 1857-9655
DOI - 10.3889/oamjms.2018.006
Subject(s) - neutrophilia , medicine , disease , pathogenesis , immunology , refractory (planetary science) , myeloid leukemia , sweet's syndrome , myeloid , leukemia , myeloid leukaemia , physics , astrobiology
Firstly described by Robert Douglas Sweet in 1964, febrile neutrophilic dermatosis is a disabling, not only cutaneous disorder, clinically characterised by fever and painful erythematous nodules, with a typical background of neutrophilia. Sweet's syndrome (SS) is a chronic inflammatory reactive disorder of unknown cause and incompletely established pathogenesis, although an interplay between genetic and environmental factors, including infections, is likely to occur. A significant part of cases has been demonstrated to be linked with malignancies, especially in the hematologic setting. Because of the underlying disease and related therapeutic measures, SS may present atypical clinical course, whereas the response to treatment is strictly dependent on the concurrent hematologic disease. Herein we describe a case of a lady who had a refractory form of SS, resulted in a paraneoplastic cutaneous disease, and AML. Surprisingly, clinical remission of SS followed cytotoxic chemotherapy while hematologic disorder obtained a further complete response.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom